戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1  were grade 1, 50% (5 episodes) were grade 2, and none were grade 3.
2 dverse events affected 71% of the patients, and 4 (7%) were grade >= 3.
3                                             The most common grade 3-4 adverse events that occurred in the phase 2 single-
4                                             The most common grade 3-4 adverse events were febrile neutropenia (22 [66%]),
5                           The most common treatment-related grade 3-4 adverse events were neutropenia (15 [50%] of 30 pat
6                                             The most common grade 3-4 adverse events were raised gamma-glutamyltransferas
7 weekly group; the most common (>=20% patients in any group) grade 3-4 adverse events were thrombocytopenia (33 [42%] of 7
8 de 3-4 atrial fibrillation occurred in one (1%) patient and grade 3-4 bleeding occurred in three (3%) patients.
9 vent and was observed in 19 patients (91%); three (14%) had grade 3-4 cytokine release syndrome.
10              Cy/Flu conditioning was the probable cause for grade 3-4 hematologic adverse events, as they occurred before
11                                                          No grade 3-4 infusion-related reactions occurred.
12 apy (CRT), no differences were observed in the incidence of grade 3-4 mucositis between treatment groups, in the ITT, PP
13                     Micturition urgency was the most common grade 3-4 study drug-related adverse event (two [1%] of 157 p
14                                             The most common grade 3-4 treatment-related adverse events were anaemia (four
15                                                          No grade 3/4 renal toxicity occurred.
16 hood cancer survivors), and at increased risk of developing grade 3-5 cardiac (4.3 [3.5-5.4] and 5.6 [4.5-7.1]), endocrin
17 eveloping severe and disabling, life-threatening, or fatal (grade 3-5) health conditions than siblings of the same age (H
18 edict posttransplant survival in patients transplanted with grade-3 acute-on-chronic liver failure (ACLF-3).
19  drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.
20 = no disease progression; grade 2 = development of varices; grade 3 = bleeding alone; grade 4 = nonbleeding single decomp
21                         Among the axi-cel-treated patients, grade >= 3 cytokine release syndrome and neurotoxicity occurr
22 had grade 1 DD, 352 (28.1%) had grade 2 DD, 168 (13.4%) had grade 3 DD, and 51 (4.1%) had indeterminate DD grade.
23        During dose finding, 1/6 patients experienced a DLT (grade 3 decrease in ejection fraction).
24                                           Treatment-related grade >=3 dysphagia and esophagitis occurred in 3.2% and 5.0%
25 verall adverse event rate was 14% (43 of 307), including 11 grade 3 events and three grade 4 events according to the Comm
26 nce was observed in the 3-year incidence of late RT-related grade >= 3 GI (2.5% v 3.9%) or genitourinary toxicity (2.9% v
27 h-grade serous, clear cell, or any poorly differentiated or grade 3 histological subtype, or any FIGO (1988) stage IIB-IV
28 oint was safety and we observed 6 of 28 patients (21%) with grade >=3 immune-related adverse events, consisting of asympt
29                                                Incidence of grade >= 3 late RT-related toxicities was compared by log-ran
30 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44).
31    Median OS was 13 months (95% CI 10-18) for patients with grade >= 3 neutropenia and 10 months (95% CI 8-13) for patien
32                                                      Frisen grade >=3 (odds ratio [OR] 10.21, P < .0053) and cases with w
33 sease (GVHD), all evaluated through 100 days after HCT, and grade 3 or 4 adverse events (AEs) within 2 weeks after vaccin
34 e exposures in study weeks 1 and 2 and treatment-associated grade 3 or 4 adverse events at least possibly related to stud
35  (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was similar in the
36                                             The most common grade 3 or 4 adverse events were hypertension (88 [27%] of 33
37  Thirteen percent of patients (n = 5) had treatment-related grade 3 or 4 adverse events.
38 espectively), and hypertension (21% and 10%, respectively); grade 3 or 4 immune-related AEs included hepatitis (0% and 13
39                                46 (34%) of 134 patients had grade 3 or 4 treatment-related adverse events, with the most
40 t, or end-organ disease), nonrelapse mortality, and severe (grade 3 or 4) graft-versus-host disease (GVHD), all evaluated
41 costeroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicit
42                                                          No grade 3 or higher adverse events are seen.
43                                The most frequently reported grade 3 or higher adverse events were abnormal blood chemistr
44                               Overall, 21 adverse events of grade 3 or higher were recorded.
45 ases of thrombocytopenia and neutropenia, none of which was grade 3 or higher.
46                                   The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of
47                               11 (32%) patients experienced grade 3 or worse adverse events, of which the most common wer
48 44%) of 126 participants who started chemotherapy had acute grade 3 or worse treatment-emergent adverse events, which acc
49                       Patients had localized high-risk STS (grade 3; size, >= 5 cm) of an extremity or trunk wall, belong
50 oss of consciousness and was diagnosed with a Hunt and Hess grade 3 subarachnoid haemorrhage from a ruptured aneurysm.